These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 25039809

  • 1. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
    Iorio A, Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L.
    Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y, Hu Y, Jin J, Zhao X, Wang X, Wu R, Wu D, Yang R, Yang F, Hu Q, Wang J, Fang H, Engl W.
    Clin Appl Thromb Hemost; 2021 Nov; 27():1076029621989811. PubMed ID: 33587652
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J, Refacto St Louis Study Group.
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
    Taki M, Fukutake K, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Arai M, Takagi H, Uchikawa H, Engl W, Shirahata A.
    Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
    [Abstract] [Full Text] [Related]

  • 11. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM, rAHF-PFM Clinical Study Group.
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E, KOGENATE Bayer European PMS Study Group.
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M, EUHASS participants.
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 19. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, Schroth P, Ewenstein B.
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [Abstract] [Full Text] [Related]

  • 20. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S.
    Drugs; 2012 May 07; 72(7):987-1007. PubMed ID: 22564135
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.